TY - JOUR
T1 - Other Targetable Sarcomas
AU - Pires de Camargo, Veridiana
AU - van de Rijn, Matt
AU - de Alava, Enrique
AU - Madoz-Gúrpide, Juan
AU - Pilotti, Silvana
AU - von Mehren, Margaret
AU - Pedeutour, Florence
AU - Maki, Robert G.
AU - Rutkowski, Piotr
AU - Thomas, David M.
PY - 2009/8
Y1 - 2009/8
N2 - Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
AB - Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=67949108223&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2009.06.008
DO - 10.1053/j.seminoncol.2009.06.008
M3 - Article
C2 - 19664496
SN - 0093-7754
VL - 36
SP - 358
EP - 371
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 4
ER -